MIRA
INFORM REPORT
|
Report Date : |
04.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
SAMI PHARMACEUTICALS (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
34-C, Block-6,
P.E.C.H.S., |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1971 |
|
|
|
|
Com. Reg. No.: |
3227/19710907 |
|
|
|
|
Legal Form : |
Private Limited
Company |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Business Name
SAMI PHARMACEUTICALS (PRIVATE) LIMITED
Full Address
|
Registered Address |
|
34-C, Block-6,
P.E.C.H.S., |
|
Tel |
92 (21) 4527490,
4527491, 4527492 |
|
Fax |
92 (21) 4549190,
4549190 |
|
Email |
Short Description Of Business
|
Nature of
Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
1971 |
|
Registration # |
3227/19710907 |
Factory Location
|
Address |
F-95, Off. |
|
Tel # |
92 (21) 2578081,
2578082, 2578083 |
|
Fax # |
92 (21) 2563934 |
Auditors
Mohammad Farooq
& Co
(Chartered Accountants)
Legal Status
Subject Company was established as a Private Limited Company in 1971
Authorised Capital
Rs. 2,000,000/- divided into 20,000 shares of Rs. 100/- each
Issued & Paid up Capital
Rs. 1,671,100/- divided into 16,711 shares of Rs. 100/- each
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Shamim Ahmed Mr. Hafiz
Ferozuddin Mr. Abdul Salam |
Pakistani Pakistani Pakistani |
X-37, Block-6, P.E.C.H.S., 29, Al Hamra Co-operative Housing Society,
373, Block-3, B.Y.J.C.H.S., |
Business Business Business |
Chief Executive Director Director |
Shareholders
|
Names |
No. of Shares |
|
Mr. Hafiz
Ferozuddin Mrs Rehana
Khatoon Mr. Amir Hafiz M. Umair Hafiz M. Saad Mrs. Farhana Mr. Shamim Ahmed Mr. Junaid Mr. Ovais Mr. Zubair Mr. Shoaib Mr. Abdul Salam Mrs. Humaira Mrs. Imrana Mrs. Ayesha Feroz |
257 1,050 3,376 387 520 1,523 83 1,528 3,389 1,407 1,200 269 719 503 500 |
Associates
A. Subsidiary
None
B. Associated
Companies
- Do -
Products
Ammoidin, Antial, Buepron, Caricef, Chymotrip, Conspic, Dicloran, Diclorep, Disgren, Euphen, Flavin, Klint, Klinz, Lospan Plus, Movax, Moxypen, Neucef, Novidat, Oxidil, Pace, Pencit, Penorit, Peridone, Provas, Pulsate, Samerol, Santovir, Sedil, Teph 20, Trimetabol, Uhasil, Ulcerax, Zolen
Number of Employees
146 -
160
Actual Capacity & Production
The capacity and production of the Company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.
Annual Sales Volume
Year In
Pak Rupees
2005 150,000,000/- (Estimated)
Distributors
Mainly in all important cities of
Bankers and their addresses
(1) Askari Commercial Bank Limited, Shahrah-e-Faisal Branch,
(2) Habib
Metropolitan Bank Limited, Hirani Centre,
(3) Al-Baraka Islamic Bank, Lakhani Centre,
Financial Position
Sound
Memberships
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.87 |
|
|
1 |
Rs. 119.10 |
|
Euro |
1 |
Rs. 78.50 |
Comments
Subject is a well-established
company having fine track. Directors are reported as experienced, respectable
and having satisfactory means of their own. Their trade relations are reported
as fair. Payments are usually correct and as per commitments. The Company can
be considered for normal business dealings at usual trade terms and conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)